ID   KYSE-140
AC   CVCL_1347
SY   KYSE 140; Kyse-140; KYSE140; Kyse140
DR   BTO; BTO:0006197
DR   CLO; CLO_0007128
DR   EFO; EFO_0006626
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 918
DR   BioSample; SAMN03471046
DR   BioSample; SAMN10987809
DR   cancercelllines; CVCL_1347
DR   Cell_Model_Passport; SIDM01032
DR   CGH-DB; 277-1
DR   CGH-DB; 9226-4
DR   ChEMBL-Cells; CHEMBL3308752
DR   ChEMBL-Targets; CHEMBL1075484
DR   Cosmic; 753573
DR   Cosmic; 801330
DR   Cosmic; 918524
DR   Cosmic; 1123337
DR   Cosmic; 1581072
DR   Cosmic; 2267698
DR   Cosmic; 2698433
DR   Cosmic-CLP; 753573
DR   DepMap; ACH-000823
DR   DSMZ; ACC-348
DR   DSMZCellDive; ACC-348
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 753573
DR   GEO; GSM590303
DR   GEO; GSM827546
DR   GEO; GSM887247
DR   GEO; GSM888322
DR   GEO; GSM1374607
DR   GEO; GSM1670016
DR   IARC_TP53; 7679
DR   JCRB; JCRB1063
DR   LiGeA; CCLE_467
DR   LINCS_HMS; 50024
DR   LINCS_LDP; LCL-1547
DR   PharmacoDB; KYSE140_801_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1347
DR   PubChem_Cell_line; CVCL_1347
DR   Wikidata; Q54900803
RX   PubMed=1728357;
RX   PubMed=7913084;
RX   PubMed=8575860;
RX   PubMed=9033652;
RX   PubMed=11092977;
RX   PubMed=15172977;
RX   PubMed=16045545;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 27.4 hours (PubMed=1728357); ~24 hours (DSMZ=ACC-348).
CC   HLA typing: A*02:07,26:02; B*40:06,46:01; C*01:02,08:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=8575860).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.5%; Native American=0%; East Asian, North=83.8%; East Asian, South=6.46%; South Asian=0%; European, North=0%; European, South=6.23% (PubMed=30894373).
CC   Discontinued: JCRB; JCRB1063; probable.
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 12
ST   D16S539: 10,12
ST   D18S51: 14
ST   D19S433: 13,15
ST   D21S11: 29
ST   D2S1338: 17
ST   D3S1358: 18
ST   D5S818: 10
ST   D7S820: 10 (DSMZ; PubMed=25877200)
ST   D7S820: 10,11 (Cosmic-CLP)
ST   D8S1179: 10
ST   FGA: 22,23
ST   Penta D: 9
ST   Penta E: 16,17
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   PubMed=1728357; DOI=10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C;
RA   Shimada Y., Imamura M., Wagata T., Yamaguchi N., Tobe T.;
RT   "Characterization of 21 newly established esophageal cancer cell
RT   lines.";
RL   Cancer 69:277-284(1992).
//
RX   PubMed=7913084; DOI=10.1002/ijc.2910580224;
RA   Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H.,
RA   Fukumoto M.;
RT   "Analysis of gene amplification and overexpression in human
RT   esophageal-carcinoma cell lines.";
RL   Int. J. Cancer 58:291-297(1994).
//
RX   PubMed=8575860; DOI=10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.0.CO;2-C;
RA   Tanaka H., Shibagaki I., Shimada Y., Wagata T., Imamura M.,
RA   Ishizaki K.;
RT   "Characterization of p53 gene mutations in esophageal squamous cell
RT   carcinoma cell lines: increased frequency and different spectrum of
RT   mutations from primary tumors.";
RL   Int. J. Cancer 65:372-376(1996).
//
RX   PubMed=9033652; DOI=10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.0.CO;2-C;
RA   Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.;
RT   "Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b)
RT   genes in 30 esophageal squamous-cell-carcinoma cell lines.";
RL   Int. J. Cancer 70:437-442(1997).
//
RX   PubMed=11092977; DOI=10.1111/j.1349-7006.2000.tb00895.x;
RA   Pimkhaokham A., Shimada Y., Fukuda Y., Kurihara N., Imoto I.,
RA   Yang Z.-Q., Imamura M., Nakamura Y., Amagasa T., Inazawa J.;
RT   "Nonrandom chromosomal imbalances in esophageal squamous cell
RT   carcinoma cell lines: possible involvement of the ATF3 and CENPF genes
RT   in the 1q32 amplicon.";
RL   Jpn. J. Cancer Res. 91:1126-1133(2000).
//
RX   PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172;
RA   Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K.,
RA   Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.;
RT   "Frequent silencing of low density lipoprotein receptor-related
RT   protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in
RT   esophageal squamous cell carcinoma.";
RL   Cancer Res. 64:3741-3747(2004).
//
RX   PubMed=16045545; DOI=10.1111/j.0959-9673.2005.00431.x;
RA   Ban S., Michikawa Y., Ishikawa K.-i., Sagara M., Watanabe K.,
RA   Shimada Y., Inazawa J., Imai T.;
RT   "Radiation sensitivities of 31 human oesophageal squamous cell
RT   carcinoma cell lines.";
RL   Int. J. Exp. Pathol. 86:231-240(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//